Wednesday, January 04, 2017 10:09:17 PM
$NVLS, 2.40 I like this one for a swing. Company had news yesterday evening looking for strategic alternatives/merger, etc. Has $4.26 in cash value, 15M O/S and 8M Float per Yahoo Finance.
Scroll down for chart.
Nivalis Therapeutics Reports Review of Strategic Alternatives, Has Engaged Ladenburg Thalmann To Act As Advisor
6:00 pm ET January 3, 2017 (Benzinga) Print
Nivalis Therapeutics, Inc. (NASDAQ: NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (CF), today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from its clinical assets and cash resources. Nivalis has engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor for this process. In conjunction with the exploration of strategic alternatives, the Company also intends to streamline its operations in order to preserve its capital and cash resources.
The Board has established a Special Committee to explore and evaluate strategic alternatives. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. There can be no assurance, however, that this process will result in any such transaction.
In parallel with this process, the Company intends to complete its ongoing SNO-7 trial of cavosonstat in patients with CF who are currently taking KalydecoTM (ivacaftor), which is expected to be completed in the first quarter of 2017.
[/img]
Scroll down for chart.
Nivalis Therapeutics Reports Review of Strategic Alternatives, Has Engaged Ladenburg Thalmann To Act As Advisor
6:00 pm ET January 3, 2017 (Benzinga) Print
Nivalis Therapeutics, Inc. (NASDAQ: NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (CF), today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from its clinical assets and cash resources. Nivalis has engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor for this process. In conjunction with the exploration of strategic alternatives, the Company also intends to streamline its operations in order to preserve its capital and cash resources.
The Board has established a Special Committee to explore and evaluate strategic alternatives. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. There can be no assurance, however, that this process will result in any such transaction.
In parallel with this process, the Company intends to complete its ongoing SNO-7 trial of cavosonstat in patients with CF who are currently taking KalydecoTM (ivacaftor), which is expected to be completed in the first quarter of 2017.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
